BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24865355)

  • 1. Growth inhibition effects of isoalantolactone on K562/A02 cells: caspase-dependent apoptotic pathways, S phase arrest, and downregulation of Bcr/Abl.
    Cai H; Meng X; Li Y; Yang C; Liu Y
    Phytother Res; 2014 Nov; 28(11):1679-86. PubMed ID: 24865355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression.
    Yang C; Yang J; Sun M; Yan J; Meng X; Ma T
    IUBMB Life; 2013 May; 65(5):435-44. PubMed ID: 23441067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Isoalantolactone Inhibits Proliferation of K562/A02 Cells through Caspase-Dependent Apoptotic Pathway].
    Guan YH; Zhang XD; Cai H; Yang CH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):110-114. PubMed ID: 28245385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
    Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z
    Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
    Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM
    Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
    Cai H; He X; Yang C
    Phytother Res; 2018 Sep; 32(9):1764-1769. PubMed ID: 29701267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
    Amarante-Mendes GP; Naekyung Kim C; Liu L; Huang Y; Perkins CL; Green DR; Bhalla K
    Blood; 1998 Mar; 91(5):1700-5. PubMed ID: 9473236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
    Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
    Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
    Yin SS; Chen C; Liu Z; Liu SL; Guo JH; Zhang C; Zhang QW; Gao FH
    Cell Cycle; 2023 Jun; 22(12):1407-1420. PubMed ID: 37202916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
    Mao X; Yu CR; Li WH; Li WX
    Cell Res; 2008 Aug; 18(8):879-88. PubMed ID: 18663379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoalantolactone inhibits constitutive NF-κB activation and induces reactive oxygen species-mediated apoptosis in osteosarcoma U2OS cells through mitochondrial dysfunction.
    Di W; Khan M; Rasul A; Sun M; Sui Y; Zhong L; Yang L; Zhu Q; Feng L; Ma T
    Oncol Rep; 2014 Oct; 32(4):1585-93. PubMed ID: 25109871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
    Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
    Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.